


Corrigendum

Corrigendum to “Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3⁺ CD8⁺ T Cells and Survival in Diffuse Large B Cell Lymphoma”

Tingting Zhang,¹ Tianyuan Ren,¹ Zheng Song,¹ Jing Zhao,¹ Lei Jiao,² Zhenzhen Zhang,³ Jin He,¹ Xianming Liu,¹ Lihua Qiu,¹ Lanfang Li,¹ Shiyong Zhou,¹ Bin Meng,⁴ Qiongli Zhai,⁴ Xiubao Ren,⁵ Zhengzi Qian,¹ Xianhuo Wang ,¹ and Huilai Zhang¹

¹Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin, China

²Panovue Biological Technology Co., Ltd., Beijing, China

³Marvel Medical Laboratory, Tianjin Marvelbio Technology Co. Ltd., Tianjin, China

⁴Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

⁵Department of Immunology/Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

Correspondence should be addressed to Lanfang Li; 44936734@qq.com, Zhengzi Qian; tjzhengziquan@163.com, Xianhuo Wang; tjzly_xianhuow@163.com, and Huilai Zhang; huilai_zhang@163.com

Received 21 January 2021; Accepted 21 January 2021; Published 8 February 2021

Copyright © 2021 Tingting Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3⁺ CD8⁺ T Cells and Survival in Diffuse Large B Cell Lymphoma” [1], the survival data for the Tim-3⁺ TIL and Tim-3⁻ TIL groups was mistakenly reversed by the authors during manuscript preparation. The following sections should be corrected.

(i) The abstract section should be corrected from:

“Multiplexed immunofluorescence revealed that patients with Tim-3-expressing tumor-infiltrating lymphocytes (Tim-3⁺ TILs) exhibited poor outcomes than those with Tim-3⁻ TILs ($p = 0.041$). The median survival times of these patients were 65.0 (95% confidence interval (CI): 71.2–88.6) and 79.9 months (95% CI: 54.4–75.6), respectively.”

To:

“Multiplexed immunofluorescence revealed that patients with Tim-3-expressing tumor-infiltrating lymphocytes (Tim-3⁺ TILs) exhibited poor outcomes than those with Tim-3⁻ TILs ($p = 0.041$). The median survival times of these patients were 65.0 (95% confidence interval (CI): 54.4–75.6) and 79.9 months (95% CI: 71.2–88.6), respectively.”

(ii) Section 3.4, “Prognostic value of Tim-3⁺ TILs and exhausted Tim-3⁺ CD8⁺ T cells in DLBCL,” should be corrected from:

“The median survival times for patients with Tim-3⁺ TILs and Tim-3⁻ TILs were 65.0 (95% confidence interval (CI): 71.2–88.6) and 79.9 months (95% CI: 54.4–75.6), respectively.”

To:

“The median survival times for patients with Tim-3⁺ TILs and Tim-3⁻ TILs were 65.0 (95% confidence interval (CI): 54.4–75.6) and 79.9 months (95% CI: 71.2–88.6), respectively.”

References

- [1] T. Zhang, T. Ren, Z. Song et al., “Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3⁺ CD8⁺ T Cells and Survival in Diffuse Large B Cell Lymphoma,” *Journal of Immunology Research*, vol. 2020, Article ID 6968595, 9 pages, 2020.